First-line NSCLC – Compelling Activity Across All PD-L1 Subgroups

In first-line non-small cell lung cancer (NSCLC) patients with high PD-L1 expression (TPS ≥50%), CS2009 monotherapy achieved an objective response rate (ORR) of 81.3% and a disease control rate (DCR) of 100.0%, with consistent benefit across squamous (ORR: 87.5%) and non‑squamous (ORR: 75.0%) histologies. In the PD-L1-negative/low  population (TPS ≤5%) squamous NSCLC cohort, CS2009 in combination with chemotherapy achieved an ORR of 75.0% and a DCR of 100.0%; notably, PD-L1-negative patients within this cohort achieved an ORR of 100.0%; the current efficacy readout remains immature due to the short follow‑up for most patients in this cohort.

(0) comments

Welcome to the discussion.

Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
PLEASE TURN OFF YOUR CAPS LOCK.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.